Polyfunctional CD4+ T-cell induction in neutralizing antibody-triggered control of simian immunodeficiency virus infection

Journal of Virology

Volumn 83, Issue 11, 2009, Pages 5514-5524

  Yamamoto, Takuya ^a,b   Iwamoto, Nami ^b   Yamamoto, Hiroyuki ^b   Tsukamoto, Tetsuo ^b   Kuwano, Tetsuya ^b   Takeda, Akiko ^b   Kawada, Miki ^b   Tsunetsugu Yokota, Yasuko ^a   Matano, Tetsuro ^a,b,c  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GAMMA INTERFERON; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION CONTROL; LYMPHOCYTE ACTIVATION; MACACA; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION; ACUTE PHASE RESPONSE; ANIMAL; CD8+ T LYMPHOCYTE; DRUG EFFECT; IMMUNIZATION; IMMUNOLOGY; MONKEY DISEASE;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS;

ACUTE-PHASE REACTION; ANIMALS; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GENE PRODUCTS, GAG; IMMUNIZATION; MACACA MULATTA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 66149122304     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00145-09     Document Type: Article

References (52)

1. + T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204:2473-2485.
2. Arguello, J. R., A. M. Little, E. Bohan, J. M. Goldman, S. G. Marsh, and J. A. Madrigal. 1998. High resolution HLA class I typing by reference strand mediated conformation analysis (RSCA). Tissue Antigens 52:57-66.
3. + T cell homeostasis and function in advanced HIV disease. Science 277:112-116.
4. + T cells. Blood 107:4781-4789.
5. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:6103-6110.
6. Brander, C., and B. D. Walker. 1999. T lymphocyte responses in HIV-1 infection: implication for vaccine development. Curr. Opin. Immunol. 11:451-459. (Pubitemid 29377915)
7. Burton, D. R., R. C. Desrosiers, R. W. Doms, W. C. Koff, P. D. Kwong, J. P. Moore, G. J. Nabel, J. Sodroski, I. A. Wilson, and R. T. Wyatt. 2004. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5:233-236. (Pubitemid 38332116)
8. + T lymphocytes with cellular maturation. J. Exp. Med. 203:2865-2877.
9. Combadiere, B., A. Boissonnas, G. Carcelain, E. Lefranc, A. Samri, F. Bricaire, P. Debre, and B. Autran. 2004. Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J. Exp. Med. 199:1585-1593. (Pubitemid 38780413)
10. + T cells. Nature 417:95-98.
11. Duvall, M. G., M. L. Precopio, D. A. Ambrozak, A. Jaye, A. J. McMichael, H. C. Whittle, M. Roederer, S. L. Rowland-Jones, and R. A. Koup. 2008. Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur. J. Immunol. 38:350-363.
12. + T cell responses in rhesus macaques. J. Immunol. Methods 288:61-79.
13. + T lymphocytes from macaques immunized with live attenuated SIV. J. Virol. 72:6315-6324.
14. + T cell response by attenuated SIV infection. J. Exp. Med. 203:2661-2672.
15. Goulder, P. J., and D. I. Watkins. 2004. HIV and SIV CTL escape: implications for vaccine design. Nat. Rev. Immunol. 4:630-640. (Pubitemid 39025048)
16. Haigwood, N. L., A. Watson, W. F. Sutton, J. McClure, A. Lewis, J. Ranchalis, B. Travis, G. Voss, N. L. Letvin, S. L. Hu, V. M. Hirsch, and P. R. Johnson. 1996. Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. Immunol. Lett. 51:107-114. (Pubitemid 26227479)
17. Harari, A., S. Petitpierre, F. Vallelian, and G. Pantaleo. 2004. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 103:966-972. (Pubitemid 38129558)
18. + T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J. Virol. 77:10900-10909.
19. + T lymphocytes. Nature 421:852-856.
20. + T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189:991-998.
21. Kawada, M., T. Tsukamoto, H. Yamamoto, N. Iwamoto, K. Kurihara, A. Takeda, C. Moriya, H. Takeuchi, H. Akari, and T. Matano. 2008. Gagspecific cytotoxic T lymphocyte-based control of primary simian immunode- ficiency virus replication in a vaccine trial. J. Virol. 82:10199-10206.
22. Kestler, H. W., III, D. J. Ringler, K. Mori, D. L. Panicali, P. K. Sehgal, M. D. Daniel, and R. C. Desrosiers. 1991. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65:651-662.
23. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunode- ficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
24. Kwong, P. D., M. L. Doyle, D. J. Casper, C. Cicala, S. A. Leavitt, S. Majeed, T. D. Steenbeke, M. Venturi, I. Chaiken, M. Fung, H. Katinger, P. W. Parren, J. Robinson, D. Van Ryk, L. Wang, D. R. Burton, E. Freire, R. Wyatt, J. Sodroski, W. A. Hendrickson, and J. Arthos. 2002. HIV-1 evades antibody-mediated neutralization through conformational masking of receptorbinding sites. Nature 420:678-682. (Pubitemid 36764500)
25. Lamoreaux, L., M. Roederer, and R. Koup. 2006. Intracellular cytokine optimization and standard operating procedure. Nat. Protoc. 1:1507-1516.
26. + T cells. Nature 434:1148-1152.
27. + T lymphocytes at suppressing simian immunodeficiency virus replication in a functional in vitro assay. J. Virol. 79:14986-14991.
28. Mascola, J. R., G. Stiegler, T. C. VanCott, H. Katinger, C. B. Carpenter, C. E. Hanson, H. Beary, D. Hayes, S. S. Frankel, D. L. Birx, and M. G. Lewis. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-210. (Pubitemid 30082367)
29. Matano, T., M. Kobayashi, H. Igarashi, A. Takeda, H. Nakamura, M. Kano, C. Sugimoto, K. Mori, A. Iida, T. Hirata, M. Hasegawa, T. Yuasa, M. Miyazawa, Y. Takahashi, M. Yasunami, A. Kimura, D. H. O'Connor, D. I. Watkins, and Y. Nagai. 2004. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J. Exp. Med. 199:1709-1718. (Pubitemid 38822004)
30. Matano, T., R. Shibata, C. Siemon, M. Connors, H. C. Lane, and M. A. Martin. 1998. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J. Virol. 72:164-169. (Pubitemid 28048825)
31. + T cells in multiple tissues during acute SIV infection. Nature 434:1093-1097.
32. + T cell proliferation. Proc. Natl. Acad. Sci. USA 98:13878-13883.
33. National Institute of Infectious Diseases. 2007. Guides for animal experiments performed at National Institute of Infectious Diseases. National Institute of Infectious Diseases, Tokyo, Japan. (In Japanese.)
34. Nishimura, Y., T. Igarashi, N. L. Haigwood, R. Sadjadpour, O. K. Donau, C. Buckler, R. J. Plishka, A. Buckler-White, and M. A. Martin. 2003. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc. Natl. Acad. Sci. USA 100:15131-15136. (Pubitemid 37518028)
35. Parren, P. W., P. A. Marx, A. J. Hessell, A. Luckay, J. Harouse, C. Cheng-Mayer, J. P. Moore, and D. R. Burton. 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodefi- ciency virus at serum levels giving complete neutralization in vitro. J. Virol. 75:8340-8347. (Pubitemid 32743706)
36. Pitcher, C. J., S. I. Hagen, J. M. Walker, R. Lum, B. L. Mitchell, V. C. Maino, M. K. Axthelm, and L. J. Picker. 2004. Development and homeostasis of T cell memory in rhesus macaques. J. Immunol. 168:29-43.
37. Poignard, P., R. Sabbe, G. R. Picchio, M. Wang, R. J. Gulizia, H. Katinger, P. W. Parren, D. E. Mosier, and D. R. Burton. 1999. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 10:431-438. (Pubitemid 29205479)
38. Richman, D. D., T. Wrin, S. J. Little, and C. J. Petropoulos. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100:4144-4149. (Pubitemid 36418171)
39. + T cell responses associated with control of viremia. Science 278:1447-1450.
40. + lymphocytes. Science 283:857-860.
41. Seder, R. A., P. A. Darrah, and M. Roederer. 2008. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8:247-258.
42. Shedlock, D. J., and H. Shen. 2003. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300:337-339. (Pubitemid 36433726)
43. Shibata, R., T. Igarashi, N. Haigwood, A. Buckler-White, R. Ogert, W. Ross, R. Willey, M. W. Cho, and M. A. Martin. 1999. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5:204-210. (Pubitemid 29068528)
44. Sun, J. C., and M. J. Bevan. 2003. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300:339-342. (Pubitemid 36433727)
45. Trkola, A., H. Kuster, P. Rusert, B. Joos, M. Fischer, C. Leemann, A. Manrique, M. Huber, M. Rehr, A. Oxenius, R. Weber, G. Stiegler, B. Vcelar, H. Katinger, L. Aceto, and H. F. Gunthard. 2005. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11:615-622. (Pubitemid 40868301)
46. Tsukamoto, T., M. Yuasa, H. Yamamoto, M. Kawada, A. Takeda, H. Igarashi, and T. Matano. 2007. Induction of CD8+ cells able to suppress CCR5-tropic simian immunodeficiency virus SIVmac239 replication by controlled infection of CXCR4-tropic simian-human immunodeficiency virus in vaccinated rhesus macaques. J. Virol. 81:11640-11649. (Pubitemid 47623796)
47. + T cells are rapidly eliminated in early SIV infection in vivo. J. Virol. 74:57-64.
48. Veazey, R. S., R. J. Shattock, M. Pope, J. C. Kirijan, J. Jones, Q. Hu, T. Ketas, P. A. Marx, P. J. Klasse, D. R. Burton, and J. P. Moore. 2003. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9:343-346. (Pubitemid 36362791)
49. Wei, X., J. M. Decker, S. Wang, H. Hui, J. C. Kappes, X. Wu, J. F. Salazar- Gonzalez, M. G. Salazar, J. M. Kilby, M. S. Saag, N. L. Komarova, M. A. Nowak, B. H. Hahn, P. D. Kwong, and G. M. Shaw. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312. (Pubitemid 36378357)
50. Yamamoto, H., M. Kawada, A. Takeda, H. Igarashi, and T. Matano. 2007. Post-infection immunodeficiency virus control by neutralizing antibodies. PLoS ONE 2:e540.
51. + cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J. Virol. 71:3120-3128.
52. + Th1 effector cells during primary HIV-1 infection. Blood 106:1660-1667.